Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

23%

3 trials in Phase 3/4

Results Transparency

25%

2 of 8 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 2

4(33.3%)

N/A

3(25.0%)

Phase 1

2(16.7%)

Phase 4

2(16.7%)

Phase 3

1(8.3%)

12Total

Phase 2(4)

N/A(3)

Phase 1(2)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials

NCT07487077Phase 4Recruiting

Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya

Role: lead

NCT06036602Phase 2Completed

Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults

Role: lead

NCT06803342Phase 2Active Not Recruiting

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy Adults

Role: lead

NCT06620003Phase 2Active Not Recruiting

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

Role: lead

NCT05817422Phase 2Completed

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Role: lead

NCT05343871Phase 4Completed

Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial

Role: lead

NCT04723602Phase 1Completed

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

Role: lead

NCT03960385Completed

Assessing the Effectiveness of Sanofi Pasteur's Dengue Vaccine (Dengvaxia) Against Hospitalization and Symptomatic Infection in the State of Parana - Brazil

Role: lead

NCT00939198Not ApplicableCompleted

Prevalence of Hookworm Infection and Community Preparedness for Hookworm Vaccine Trials in Endemic Areas of Brazil

Role: lead

NCT00473967Phase 1Terminated

Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults

Role: lead

NCT00603889Not ApplicableCompleted

Development of a Skin Test for the Na-ASP-2 Hookworm Antigen

Role: lead

NCT01308268Not ApplicableUnknown

Management of Soil-transmitted Helminthiasis and Strongyloidiasis